TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05814939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 tablets
Description: VC005 groups repeat administration for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 tablets
Description: VC005 groups repeat administration for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 tablets
Description: VC005 groups repeat administration for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib Citrate Tablets
Description: Tofacitinib Citrate groups repeat administration for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VC005 Tablets Placebo
Description: VC005 placebo groups repeat administration for 12 weeks
Study: NCT05482763

Intervention type: DRUG
Intervention: Terbinafine Topical Gel
Description: Topical application of terbinafine

Intervention type: DRUG
Intervention: Itraconazole 200 mg
Description: systemic itraconazole pulse therapy

Intervention type: DRUG
Intervention: Terbinafine 250 mg
Description: systemic terbinafine

Intervention type: DRUG
Intervention: Ciclopirox Topical Gel
Description: Topical application of ciclopirox

Intervention type: DRUG
Intervention: Amorolfine 50 MG/ML
Description: Topical application of amorolfine
Study: NCT06606665

Intervention type: OTHER
Intervention: Quality of life assessment
Description: Quality of life assessment; It will be evaluated with the Nottingham Health Profile.

Intervention type: OTHER
Intervention: Quality of life assessment
Description: Quality of life assessment; It will be evaluated with the Nottingham Health Profile.

Intervention type: OTHER
Intervention: Lower extremity muscle strength assessment
Description: Lower extremity muscle strength assessment; It will be evaluated with a 30-second sit-and-stand test.

Intervention type: OTHER
Intervention: Lower extremity muscle strength assessment
Description: Lower extremity muscle strength assessment; It will be evaluated with a 30-second sit-and-stand test.

Intervention type: OTHER
Intervention: Hand grip strength measurement test
Description: Hand grip strength measurement test; It will be evaluated with a dynamometer.

Intervention type: OTHER
Intervention: Hand grip strength measurement test
Description: Hand grip strength measurement test; It will be evaluated with a dynamometer.

Intervention type: OTHER
Intervention: Pulmonary function assessment
Description: Pulmonary function assessment; It will be evaluated by spirometry.

Intervention type: OTHER
Intervention: Pulmonary function assessment
Description: Pulmonary function assessment; It will be evaluated by spirometry.

Intervention type: OTHER
Intervention: Balance assessment
Description: Balance assessment will be done with the Wii Fit Balance Board.

Intervention type: OTHER
Intervention: Balance assessment
Description: Balance assessment will be done with the Wii Fit Balance Board.
Study: NCT06455111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Keenoa
Description: Keenoa is an artificial intelligence-enhanced, image-assisted tool, is a newly designed mobile application that may facilitate collection of dietary data. Serving as a visual food diary, individuals can upload a picture of their meal, choose the food items eaten using a preselected food list available by the app, and confirm the portion size with the presented visual aids.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ASA24
Description: The Automated Self-Administered 24-Hour (ASA24) dietary recall or record is a free, web-based tool that enables multiple, automatically coded, self-administered 24-hour diet recalls and/or single or multi-day food records, also known as food diaries.
Study: NCT06685757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felzartamab
Description: Participants will receive felzartamab by intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 0.9% saline solution by intravenous infusion.
Study: NCT06477614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC cell Vaccine
Description: Deliver DC cell vaccine into patients for anti-ancer therapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC cell Vaccine
Description: Deliver DC cell vaccine into patients for anti-ancer therapy.
Study: NCT06088576

Intervention type: OTHER
Group type: OTHER
Intervention: Together
Description: Tchat : limited to 20-30 minutes per day. With a member of the team Together. For teleconsultations : First teleconsultation, during the first month (1 to 4 sessions/month), are made by nurse and/or educator. After that, it is psychologists who do the teleconsultations (2 to 4 sessions/month). It's during 30 to 45 minutes.~Home visits, individual or group interviews on site are possible after 4 month.
Study: NCT06757816

Intervention type: PROCEDURE
Group type: OTHER
Intervention: accessory rod and iliac fixation for distal augmentation for S1 fixation.
Description: patients who were admitted to the spine unit and needed extension of fixation for L5 S1 fusion due to failed previous surgery, instability, or degenerative changes ,infection, tumors and pseudoarthrosis.
Study: NCT06316141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqua Jogging
Description: This group performed aqua jogging for 60 minutes consisting of 10 minutes warming up, 40 minutes aqua jogging or land jogging and 10 minutes cooling down.
Study: NCT06762327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: ensartinib 225mg ,PO,QD,until disease progression or intolerable toxicity
Study: NCT06762691

Intervention type: DEVICE
Intervention: MyCRO Band
Description: A 3D-printed cranial remolding orthosis

Intervention type: DEVICE
Intervention: MyCRO Band
Description: A 3D-printed cranial remolding orthosis

Intervention type: DEVICE
Intervention: Traditional CRO
Description: A traditionally manufactured cranial remolding orthosis such as the Orthomerica Starband

Intervention type: DEVICE
Intervention: Traditional CRO
Description: A traditionally manufactured cranial remolding orthosis such as the Orthomerica Starband
Study: NCT06761183

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: intracerebral stereotactic injection of NXL-001
Description: intracerebral stereotactic injection of NXL-001: with 3 subjects in each group to receive a single stereo-tactically intracerebral injection of NXL-001 at escalating doses.
Study: NCT06761027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib combined with Sintilimab
Description: Based on the mFOLFIRINOX chemotherapy regimen, combined with the safe dose of anlotinib determined in phase Ib and sintilimab.
Study: NCT06316141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Land based Jogging
Description: This group performs land jogging for 60 minutes consisting of 10 minutes warming up, 40 minutes aqua jogging or land jogging and 10 minutes cooling down.
Study: NCT06762041

Intervention type: DRUG
Intervention: Metformin treatment
Description: Interested subjects with autism are treated with metformin with a standard dosage
Study: NCT06762574

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser Therapy
Description: Low Level Laser Therapy sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low intensity light therapy. The effect is photochemical not thermal. The light triggers biochemical changes within cells and can be compared to the process of photosynthesis in plants, where the photons are absorbed by cellular photoreceptors and triggers chemical changes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Low Level Laser Therapy
Description: Placebo Low Level Laser Therapy:turning on the device with covering probe by aluminum foil and ask patient to wear sun glasses to obtain the placebo effect.
Study: NCT06760910

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS Stimulation
Description: Anode tDCS or sham stimulation for amblyopia of Adolescents

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: tDCS Stimulation
Description: Anode tDCS or sham stimulation for amblyopia of Adolescents
Study: NCT06450782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-isometric Relaxation Technique
Description: Sternocleidomastoid muscle Participants are asked to stretch their necks in a spuni position and then turn their heads as far to the side of the target muscle (right side) as possible until a sensation occurs that causes discomfort in the targeted SCM. In this case, the participants are asked to moderately isometrically contract the SKM muscle for 5 seconds and then relax for 3 seconds and the cervical spine is moved to the new barrier.~Masseter muscle Participants are positioned in a sitting position. The jaw is opened as wide as possible. The index and middle fingers of one hand are placed over the lower teeth. The weight of the hand is allowed to provide flexion and traction is applied directly to the midline. In this case, the participants are asked to moderately isometrically contract the bilateral masseter muscles for 5 seconds, then relax for 3 seconds and the participant moves his chin to the new barrier.
Study: NCT06760910

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS
Description: Anodal tDCS
Study: NCT06450782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Technique
Description: Sternocleidomastoid muscle The head is slightly elevated with the help of a folded towel to prevent discomfort that may develop depending on the position. The researcher sits in a chair next to the participant's head. The chair is placed at approximately 45° to the participant's neck. The participant's head is rotated 30° towards the opposite side of the treated side. The Graston instrument contacts the upper part of the SCM approximately 2 cm below the mastoid process.~Masseter muscle It works both ways. The Graston instrument is placed on the zygomatic process of the temporal bone, approximately 1 cm in front of the ear. The soft tissue is pressed until the bone is contacted. This connection with the periosteum is maintained and a lower tension line is created towards the mandible angle. This line of tension is continued up to the mandible, where the periosteum also comes into play. It is repeated several times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will rest for thirty minutes.
Study: NCT05350800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986369
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986369
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986369
Description: Specified dose on specified days
Study: NCT06760910

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS
Study: NCT05974657

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Lactobacillus acidophilus LA85
Description: Through a randomized double-blind placebo-controlled method, the patients were randomly divided into placebo group and probiotic intervention group, and took probiotics once a day for 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Lactobacillus acidophilus LA85
Description: Through a randomized double-blind placebo-controlled method, the patients were randomly divided into placebo group and probiotic intervention group, and took probiotics once a day for 14 consecutive days.
Study: NCT06397157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants will recieve treatment(Virtual reality) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: Participants will recieve treatment(Virtual reality) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
Study: NCT04709016

Intervention type: BEHAVIORAL
Intervention: self-questionnaire
Description: self-questionnaire assessing Chemsex's (drug use in a sexual context) consumption over the last 12 months
Study: NCT04077866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is an FDA-approved drug that is given to patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide is an FDA-approved drug that is given to patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B7-H3 CAR-T
Description: B7-H3-targeting CAR-T cells derived from patient own peripheral blood mononuclear cells will be given to patients via intracerebral injection though an Ommaya catheter
Study: NCT05742438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: Continuous intravenous infusion of lidocaine
Study: NCT06397157

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Imagery
Description: Participants will recieve treatment(Motor Imagery) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: Participants will recieve treatment(Motor Imagery) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical therapy
Description: Participants will recieve treatment(Routine physical therapy) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical therapy
Description: Participants will recieve treatment(Routine physical therapy) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
Study: NCT05530044

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social diffusion intervention
Description: training in communication skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social diffusion intervention
Description: training in communication skills
Study: NCT05176002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Neoadjuvant Camrelizumab combined with radiotherapy
Study: NCT06397157

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical therapy
Description: Participants will recieve treatment(Routine physical therapy) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
Study: NCT05742438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine IV
Description: Continuous intravenous infusion of dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine
Description: intrathecal morphine injection
Study: NCT06386133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MS Boost
Description: remote monitoring digital tool based on functional tests (walking, dexterity, vision and cognition). These digital tests may be combined with a fatigue assessment via questionnaires and, if needed, a telerehabilitation program. This program includes an algorithm comprising fatigue management advice and/or physical activity recommendations personalised to the patients, aimed at improving fatigue-related symptoms. The patient can use the telerehabilitation program without supervision

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: General fatigue tips are given to patients who suffering from chronic fatigue such as stop smoking, eat a healthy diet...
Study: NCT05605392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deinstitutionalization process
Description: Phase 1: Comprehensive geriatric assessment to evaluate who might be a candidate for deinstitutionalization.~Phase 2: Intervention:~1. Support plan: design a plan agreed upon with the participant to provide resources to the person's needs and which guarantees support during the transition and beyond.~2. Transition process: progressive withdrawal of support in the institution and implementation of support and adaptation in the community, with different types of accommodation depending on the needs and preferences of each participant. Coordination with primary care teams, social services, and other community resources.~3. Case follow-up and gradual withdrawal of the project team. If the process does not go as the person expects, or difficulties are encountered that cannot be resolved, the participant will have the option and choice, if desired, to return to the residence at any time during the process.
Study: NCT06192186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab combined with SOX regimen
Description: Adebrelimab combined with SOX regimen preoperatively used 3 cycles(stop adebrelimab and S-1/oxaliplatin after 3 cycles and evaluate tumor staging)→ radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo combined with SOX (S-1/oxaliplatin) regimen
Description: Placebo combined with SOX (S-1/oxaliplatin) regimen preoperatively used 3 cycles (stop placebo and S-1/oxaliplatin after 3 cycles and evaluate tumor staging) → radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
Study: NCT05422014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Care Specialist (LCS)
Description: Life Care Specialist (LCS) will :~* Provide patients with individualized risk assessment for opioid misuse.~* Act as patient's Pain Coach. Providing targeted education and behavior-based pain treatment options.~* Train and provide CWC evidence based non-pharmaceutical pain management techniques, using the Community Resiliency Model.~* Use the Opioid Risk Tool (ORT) as the method to identity the risk of substance misuse.~* Provide education, support and resources, as well as local, state, and national resources to enhance the whole health aspect of the position. These resources include but are not limited to: written documents that outline the key concepts of the pain management techniques taught by the LCS and a list of hotlines and websites.~* LCS, when applicable, will provide education for caretakers on the risk of opioid use and the non -pharmaceutical pain management protocol.~* Provide follow up for all patients in intervention group.
Study: NCT05266183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous Variety
Description: 3 different foods served

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous Variety
Description: 3 different foods served

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-Food
Description: 1 food served

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-Food
Description: 1 food served

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small Portion
Description: Small meal portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small Portion
Description: Small meal portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Portion
Description: Large meal portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Portion
Description: Large meal portion size
Study: NCT04226456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: Injection of a 10% solution of N-acetylcysteine through transtympanic injection in both ears
Study: NCT05445050

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS)
Description: Part A: performing CEUS with the contrast agent SonoVue® at two different doses and two different injection speeds in participants with primary breast cancer~Part B: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants undergoing neoadjuvant chemotherapy~Part C: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants with lesions of unknown dignity
Study: NCT04248972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBM
Description: A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO PBM
Description: A placebo whole body red light will be carried out during 20 minutes
Study: NCT04715659

Intervention type: DIAGNOSTIC_TEST
Intervention: Performance of step test (number of steps) for the assessment of exercise capacity
Description: The development of the step test will be designed according to the characteristics of other validated field tests - the walking tests (6-minute walk test and the incremental shuttle walking test) The step test will be performed on a 20 cm tall, single-step device with no handles. The criteria for stopping the test will be the same as described in standard operating procedures for the walking field tests, with the addition of the inability to follow the work rate for a period of 10 seconds.~The main outcome of the test will be the highest number of steps and work rate achieved.
Study: NCT05466240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT-752
Description: AT-752 for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT-752
Description: AT-752 for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT-752
Description: AT-752 for 5 days
Study: NCT04841759

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 8 week exercise program, nutritional \& psychological consultation
Study: NCT05466240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for 5 days
Study: NCT05344859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Automated Health Coaching
Description: This intervention will involve health coaching delivered by Artificial intelligence (AI). The automated health coaching mechanism will be coupled with AI-based responses, and recent advancements have made the voices generated through the AI, almost human-like voices. Every week participants enrolled in automated health coaching intervention will receive a health coaching and goal-setting call that will help guide the participants in managing their Type 2 Diabetes Mellitus. This technology-driven study group will inform us whether trained human coaches are required or if the automated technologies are sufficient to create clinically meaningful HbA1c improvements.
Study: NCT04841759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 8 week exercise program, nutritional \& psychological consultation